

History of Value Creation

Since our founding in 1920 as a pioneer in hormone preparations, we have unerringly continued on our journey, while always keeping in mind our essential mission as a company that is directly linked to life and health. In 2021, we transitioned to a holding company structure, and took a new step toward the next 100 years. We will continue to respond to the changing times and environment, and contribute to society as we evolve into a total healthcare company.

2021 –

Aim for further growth

ASKA Pharmaceutical Holdings' Medium-Term Management Plan 2025 was launched in 2021. In conjunction with the shift to a holding company structure, the Company not only aims to build a flexible organization that is capable of swift decision-making, but also to achieve further sustainable growth for the entire Group by further strengthening its governance structure.

2005 – 2021

Formation of ASKA Pharmaceutical Co., Ltd.

In 2005, ASKA Pharmaceutical Co., Ltd. was established to develop and market new drugs, specializing in the three priority areas of internal medicine, obstetrics and gynecology (Ob/Gyn), and urology with the aim of becoming a competitive specialty pharma company. The company took on challenges for the next stage, such as strengthening efforts for generic drugs that meet the needs of the times.



FY2023

¥62,843 million

2022

Enforcement of Revised Act on the Promotion of Women's Active Engagement in Professional Life

45,849

2016

Enforcement of Act on the Promotion of Women's Active Engagement in Professional Life

1986

Enforcement of Act on Equal Opportunity and Treatment between Men and Women in Employment

24,390

1992

Enforcement of Childcare Leave Act*

23,537

1975

International Women's Year

12,409

4,929


940

294

4.115

0.038

Net sales (Millions of yen)



1945

Women's suffrage in Japan